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Abstract  
There is a consensus that the development of premenstrual dysphoric states is 
related to cyclical change in gonadal hormone secretion during the menstrual cycle. 
However, results from studies seeking to link symptom severity to luteal phase 
progesterone concentration have been equivocal. In the present study we evaluated 
not only the absolute concentrations of progesterone but also the kinetics of the 
change in progesterone concentration in relation to development of premenstrual 
symptoms during the last 10 days of the luteal phase in a population of 46 healthy 
young adult Brazilian women aged 18-39 years, mean 26.5±6.7 years. In participants 
who developed symptoms of premenstrual distress, daily saliva progesterone 
concentration remained stable during most of the mid-late luteal phase, before 
declining sharply during the last 3 days prior to onset of menstruation. In contrast, 
progesterone concentration in asymptomatic women underwent a gradual decline 
over the last 8 days prior to menstruation. Neither maximum nor minimum 
concentrations of progesterone in the two groups were related to the appearance or 
severity of premenstrual symptoms. We propose that individual differences in the 
kinetics of progesterone secretion and/or metabolism may confer differential 
susceptibility to the development of premenstrual syndrome.  
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INTRODUCTION 
 
Premenstrual syndrome (PMS) refers to a cluster of adverse psychological and 
physical symptoms experienced by many women in the late luteal phase of their 
menstrual cycle. The most commonly reported psychological symptoms included 
anger and irritability, mood swings/tearfulness, fatigue/lack of energy and food 
cravings, whilst physical symptoms include bloating, weight gain and breast 
tenderness (Dennerstein et al, 2011; 2012; Tschudin et al, 2010). Although the 
syndrome is not distinguished by a specific set of symptoms, there is a consensus 
that certain symptoms should be present for 2 or more days during the 14 days prior 
to menstruation, and subside by the end of the menstrual flow (Halbreich et al, 2007). 
 
Premenstrual dysphorias are extremely common. In large surveys of European and 
Canadian women up to 90% of participants reported experiencing one or more 
symptoms. Up to 30% felt them to be considerably bothersome, whilst a smaller 
proportion of women (3-8%) who experienced severe and debilitating symptoms, 
were diagnosed with premenstrual dysphoric disorder (PMDD; American Psychiatric 
Association, 2013), which is considered a distinct psychiatric disorder (Halbreich et 
al, 2003; Tschudin et al, 2010; Wittchen et al, 2002). It is not clear however, whether 
PMS and PMDD are separate entities or whether PMDD is an extreme form of PMS. 
However, since the incidence of PMS is some 10-fold higher than PMDD; its effects 
are far more wide-reaching, due to the negative impact on family, friends and work 
colleagues as well as the individual herself. PMS and PMDD are undoubtedly 
multifactorial; at least three clinical subtypes have been recognised (Dennerstein et 
al, 2011; Freeman et al, 2011). Risk factors include high body mass index, stress, 
smoking, and early life emotional and physical abuse (Bertone-Johnson et al, 2010; 
2014; Dennerstein et al, 2011). A genetic component is another contributory factor 
(Jahanfar et al, 2011).  
 
Whilst it is well established that the menstrual cycle modulates the integration of 
emotional and cognitive processing in women (Hoyer et al, 2013), not all women 
develop premenstrual symptoms. In those who do, the main trigger factor is the 
cyclical production of sex hormones during the ovarian cycle (O’Brien et al, 2011). 
Apart from rare cases (O’Brien et al, 2011) premenstrual symptoms do not occur in 
anovulatory cycles (Muse et al, 1984; Hammarback et al, 1991) or following 
oophorectomy (Cronje et al, 2004). The luteal phase of the menstrual cycle, when 
premenstrual symptoms appear, is characterized by significant changes in secretion 
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of progesterone: production increases rapidly following ovulation and remains 
elevated throughout the luteal phase, before returning to basal levels prior to the 
onset of menstruation. Progesterone passes readily through the blood brain barrier 
(Pardridge et al, 1980). In post menopausal women (low stable progesterone 
concentration) administration of low doses of progesterone, which raised the 
concentration of the native steroid and its neuroactive metabolite allopregnanolone 
into the physiological range, induced negative mood whilst higher doses induced 
positive mood (Andréen et al, 2006; 2009).  
 
Although we are not aware of comparable studies on women with PMS, several 
studies in PMDD sufferers have investigated the relationship between severity of 
symptoms and plasma concentration of progesterone during the luteal phase. The 
results from these studies have been equivocal, with reports of decreased (Rapkin et 
al, 1997; Wang et al 1996; Ziomkiewicza et al 2012), increased (Bäckström et al, 
1983; Girdler et al. 2001; Hammarbäck et al, 1989; Redei and Freeman, 1993; Watts 
et al. 1985) or no difference (Hsiao et al, 2004; Rubinow et al. 1988) in luteal phase 
concentration of progesterone or its neuroactive metabolite allopregnanolone in 
women with PMDD versus asymptomatic controls. Interestingly, a more recent study 
has proposed an inverted U-shaped curve relationship between the severity of 
negative mood symptoms and allopregnanolone serum concentration  (Bäckström et 
al, 2014). 
 
In an effort to resolve this conundrum, we carried out a study in a population of 
healthy adult women in whom we made daily assessments of the presence of PMS-
like symptoms during the luteal phase and the concentration of progesterone in the 
saliva. We considered not only the absolute concentrations of progesterone but also 
the kinetics of the change in progesterone concentration during the luteal phase. We 
found that neither maximum nor minimal concentrations of progesterone measured 
during the luteal phase could be linked to the appearance or severity of premenstrual 
symptoms. However, in the women who experienced significant symptoms of 
premenstrual distress, progesterone concentration remained stable during most of 
the luteal phase before declining sharply during the last 3 days. In contrast, 
progesterone concentration in asymptomatic women underwent a gradual declined 
over the final 8 days prior to menstruation. 
 
METHODS 
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1.1 Participants 
The sample was composed of healthy female volunteers, aged between 18 and 40 
years, who were recruited from the local university population. The volunteers were 
invited through print ads, e-mail and social networks to participate in research into 
the menstrual cycle. Premenstrual dysphoric states were not mentioned. The local 
ethics committee approved the study (process number 8172/2014) and all 
participants signed a consent form. We included women who reported regular 
menstrual cycles and who had not used hormonal contraceptives in the last three 
months. Since the presence of other medical conditions might interfere with the 
evaluation of premenstrual symptoms, we excluded participants with a history of past 
diagnosis of severe mental illness, such as schizophrenia, bipolar disorder, major 
depressive disorder, obsessive-compulsive disorder, or who met criteria for any 
current psychiatric disorder. We also excluded women with a current use of 
psychoactive substances (except alcohol and tobacco), psychiatric medications or 
suspected pregnancy. 
 
1.2 Clinical assessment 
The absence of psychiatric diagnosis was confirmed by the application of the 
Structured Clinical Interview for DSM-IV (SCID) (First et al, 1997), no patient version, 
translated and adapted to Portuguese (Del-Ben et al, 2001). The menstrual cycle 
was characterized by means of a questionnaire specifically developed for this study, 
when information regarding the duration of the menstrual cycle in the last 3 months, 
the regularity of the menstrual cycles, and the date of the last period were registered. 
Screening and diagnostic interviews, and monitoring were performed by research 
assistants (nurses, psychologists) familiar with clinical research and properly trained 
in the assessment tools used in this study. These research assistants were also 
involved in the recruitment of participants, as well as telephone calls and face-to-face 
contacts, in order to ensure that the procedures for data collection were met properly. 
The next ovulatory date (Ov) for participants was estimated from the date of their last 
menstrual period (LMP) and the average duration of their menstrual cycles (MC) 
according to the following formula: Ov = LMP + MC - 14. If the interview happened 
between Ov and LMP, the volunteer was asked to contact the research assistants on 
the first day of her next period so that the Ov could be calculated. Participants were 
instructed to collect daily saliva samples and to complete symptom questionnaires 
(described below) during their luteal phase from the time of their estimated day of 
ovulation to the onset of menses or for 20 days, whichever was the shorter. 
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1.3 Premenstrual symptoms 
The occurrence of premenstrual symptoms was measured by the short form of the 
Daily Record of Severity Problems Scale (DRSP, Endicott et al. 2006), translated into 
Portuguese. The DRSP is a 14-item self-report instrument, which accesses the 
presence of symptoms of common occurrence in the premenstrual period and their 
impact in the global functioning. The first 11 items of the DRSP are related to the 
following symptoms: depressed mood; anxiety; mood swings; irritability; less interest 
in usual activities; difficulty in concentration; lethargy; increased appetite; sleeping 
problems; feeling out of control; and physical symptoms. The 3 functional items 
evaluate the consequences of the reported symptoms on the quality/frequency of 
productivity, social activity and relationships. Each participant was directed to 
evaluate the occurrence of symptoms at the end of each day by applying a score on 
a 6-point scale: 1 = not at all, 2 = minimal 3 = mild; 4 = moderate, 5 = severe, 6 = 
extreme.  Although initially designed to reflect DSM-IV criteria for PMDD, the DRSP 
can also be used to assess lesser degrees of severity of the premenstrual syndrome 
to track daily levels of severity of symptoms and impairment (Endicott et al, 2006).  
We recorded the occurrence of premenstrual symptoms daily, from the 14th day of 
the menstrual cycle based on the total score in the DRSP. As a reference point to 
assess the development of premenstrual symptoms we used the mean of the total 
score of the DRSP on the first two days of the analysis period i.e. in the early luteal 
phase 9 and 10 days prior to onset of menstruation. We defined symptomatic 
participants as individuals in whom the daily total DRSP score (sum of response to 
the 14 questions) increased  >30% above the reference level in the early luteal 
phase on at least two successive days. Asymptomatic participants were defined as 
those in whom the daily total DRSP score did not vary by more than 30% at any time 
during the data collection period. No woman in this study met the criteria for 
premenstrual dysphoric disorder. 
 
1.4 Salivary progesterone collection 
The participants received a pack of collection aids and tubes for saliva collection 
(Salimetrics) pre-labeled with an identification code, and the date and time of 
collection. They also received written instructions about the procedures involved in 
saliva collection. They were told to perform the saliva collection at the time of 
awakening, before getting up and still in bed. They were asked to avoid drinking, 
eating and brushing teeth before saliva collection. From the 14th day of the 
menstrual cycle onwards, participants collected samples and stored the tubes in 
home freezers or in a domestic refrigerator, for up to 4 days. Previous studies have 
 7 
shown that progesterone in saliva samples is unaffected by storage for at 4oC for 5 
days. (Gröschl et al, 2001; Lewis 2006). The samples were collected from the 
participant’s home by research assistants; then stored at -80oC in the laboratory prior 
to analysis.  
 
1.5 Measurement of progesterone 
Before the assays, samples were thawed to room temperature overnight, vortexed 
briefly and centrifuged at 10,000g for 5 min at 4°C in order to remove mucins and 
particulate matter from the saliva. 200μl samples of the supernatants were assayed 
for progesterone using commercially available ELISA kits (Cat. N° 1-1502 
Salimetrics, State College, PA, USA) and following the procedures recommended by 
the manufacturer. Absorbance at 450nm was measured using a EL808 Microplate 
Reader  (BioTek Instruments, Winooski, VT, USA) and the results were analysed 
using KC4 software, version 3.4. Intra-assay and inter-assay coefficients of variation 
were 9.2% and 8.3%, respectively. The sensitivity of the assays was 5.0 pg ml-1. 
 
1.6 Statistical analysis 
Statistical analysis was performed using GraphPad PRISM v.6.0 software. 
Demographic and clinical characteristics were examined using Mann-Whitney or 
Fisher exact test. DRSP scores and salivary progesterone levels were analysed 
using T-tests, Friedman’s test followed by Dunn’s multiple comparisons or Spearman 
tests as appropriate. Extra Sum-of-squares F test was used for between group 
comparison of progesterone profiles. 
 
The internal consistency of the DRSP was assessed by the Cronbach’s alpha 
coefficient with alpha above 0.70 considered as a good index of internal consistency. 
(Chronbach, 1951). For this purpose, we considered the measures taken in the early 
luteal phase (days 10 and 9 prior to menstruation) and in the late luteal phase (days 
1 and 0 prior to menstruation).  Due to our small sample size, we were not able to 
carry out a factorial analysis. We therefore looked at the internal consistency of two 
sets of items of the DRSP: the 11 items related to premenstrual symptoms and the 3 
items related to the impact of the symptoms on the global functioning.  
The reliability of each item of the DRSP was tested by the Intraclass Correlation 
Coefficient (ICC), comparing the measures taken in the early luteal phase (day 10 vs. 
day 9) and in the late luteal phase (day 1 vs. day 0). Values between 0.40 and 0.75 
are considered as a satisfactory agreement and values above 0.75 are considered 
as excellent (Fleiss, 1981).  
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RESULTS 
 
2.1 Features of the sample 
Sixty-three women were submitted to the screening interview. Eight participants were 
excluded from the study due to the use of antidepressants (n = 5), the diagnosis of 
hypothyroidism (n = 2), and the prescription, after the screening interview, of a 
hormonal contraceptive (n = 1). A further 9 participants, who were considered as 
eligible in the screening interview, declined to take part in the study after hearing 
about the procedures involved in data collection. Forty-six participants aged 18-39 
years, mean 26.5±6.7 years were recruited into the study, which was carried out 
between June and October 2015. Data from 5 participants were excluded from the 
analysis due to incomplete data sets (n=3), progesterone below the level of detection 
of the assay (n=1) and in one case when the participant embarked on a course of 
antibiotic treatment during the study.  In 6 participants menstruation had not occurred 
after 20 days of saliva collection. These women were suspected to have undergone 
atypical cycles and their data sets were therefore treated as a separate group and 
excluded from the main analysis.  
 
In the participants who menstruated, collection periods ranged from 11-19 days, 
mean 14.6±0.4 days. Thus in order to have a complete data set for each participant 
we compared data from only the last 11 days before menstruation.  
Good indices of internal consistency and reliability were obtained with Chronbach’s 
coefficient in excess of 0.7 with respect to the total score, the subscale of 
premenstrual symptoms (items 1 to 11 of the DSRP) and the subscale of impact of 
the premenstrual symptoms on the global functioning (items 12 to 14) (Table 1). 
Similarly the reliability of each symptom, tested by the interclass coefficient, 
comparing the measures taken in the early luteal phase (day 10 vs. day 9 prior to 
onset of menstruation) and in the late luteal phase (day 1 vs. day 0 prior to 
menstruation) was in the range considered satisfactory or excellent (Table 2). 
 
2.2 Premenstrual symptom scores v. salivary progesterone  
Data was analysed from 35 participants who were cycling (i.e had menstruated within 
20 days of the estimated date of ovulation). Subjective complaints measured by the 
DRSP scores showed a progressive increase during the luteal phase (Fig 1). During 
this period salivary progesterone concentration remained relatively stable during the 
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first 8 days of the collection period before declining rapidly over the last 3 days prior 
to menstruation (Fig 1).  
 
2.3.1 Symptomatic and asymptomatic participants 
Although the meand data from all participants indicated a progressive increase in 
PMS symptom scores during the luteal phase, there was considerable inter-individual 
variability. Inspection of individual data sets, considering an increase from the early 
luteal phase reference DRSP score of at least 30% as the criterion for PMS, revealed 
that two distinct subsets were present within the population: those who developed 
premenstrual symptoms (n = 22, 62.9%) and those who remained asymptomatic 
during the luteal phase (n = 13, 37.1%). No significant differences between 
symptomatic and asymptomatic participants were found regarding age (Mann-
Whitney p = 0.618), marital status (Fisher exact test, p = 0.618) and years of 
education (Fisher exact test, p = 0.524).   
 
2.3.2. Symptomatic participants  
In terms of individual symptoms, the most common complaints (moderate intensity or 
worse, score 4 or above on two or more days) were: felt nervous or irritated (55%); 
slept more; took naps; felt it more difficult to rise when needed; had trouble sleeping 
and suffered insomnia (45%); felt anxious, tense or restless (40%); had mood swings 
(eg felt suddenly sad or tearful) or was more sensitive to rejection or easily hurt 
feelings (40%); increased appetite, ate more or felt compulsion for specific foods 
(40%). In addition, 80% of participants who experienced negative psychological 
symptoms also reported being troubled by physical symptoms such as pain or breast 
enlargement, feeling of being bloated, weight gain, headaches, joint or muscle or 
other physical symptoms. 
 
In the symptomatic group the DRSP score increased steadily during the 11 days of 
data collection during the luteal phase and was significantly higher, compared to the 
first sample day, during the last 6 days prior to menstruation (Fig 2A, p<0.05 
Friedman test followed by Dunn’s multiple comparisons).  Analysis of salivary 
progesterone in the symptomatic participants over the same period prior to 
menstruation showed that progesterone concentration remained relatively stable 
during early/mid luteal phase before showing a sharp decline during the last 3 days 
prior to menstruation (Fig 2A). Thus paradoxically, DRSP scores increased when 
progesterone concentration was stable and continued to rise further as progesterone 
concentration underwent a sharp decline (Fig 2A). 
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2.3.3. Asymptomatic participants  
In the asymptomatic participants (37.1%, n=13), DRSP scores did not change 
significantly during the collection period (Fig 2B), whereas salivary progesterone 
concentration underwent a gradual linear decline (Fig 2B). The linear decline in 
progesterone concentration was not a ‘smoothing effect’ due to a misalignment of 
peaks in some subject cancelling peaks in others. When the dataset was re-analyzed  
with the peaks aligned, the progesterone profile was still best represented as a 
straight line (9y = -9.6746x + 237.91). 
 
2.3.4. Comparison between symptomatic and asymptomatic participants 
The mean length of the luteal phase (number of days between estimated ovulation 
and onset of menstruation) was similar in symptomatic and asymptomatic 
participants (14.6±0.6 vs. 14.6±0.56 days respectively, p=0.5, unpaired T-test).  
However, the DRSP score at the beginning of the data collection period was 
significantly higher in the asymptomatic group than in the participants who went on to 
develop premenstrual symptoms (29.0±2.8 v. 21.1±1.1 respectively, p<0.01). The 
salivary progesterone concentration on the first collection day for analysis (10 days 
prior to menstruation) was similar in the two groups (176.1±24.3 v. 207.8±32.9 pg/ml 
respectively, p=0.23, unpaired test). However, although the progesterone 
concentration on the final collection day (first day of menstruation) had declined to 
similar levels in both symptomatic and asymptomatic participants (147.2± 18.4 v. 
129±22.7 pg ml-1, p>0.05, unpaired T-test), there was a marked difference in the 
time course of the change in progesterone concentration between the two groups. In 
symptomatic participants the time course was best described by the third order 
polynomial function y=124.5 - 44.49x - 7.548x2 - 0.3636x3 (Extra Sum-of-squares F 
test, with a first order polynomial (linear) as the null hypothesis, v. a 3rd order 
polynomial p=0.026) (Fig. 2A), In marked contrast, progesterone concentration in the 
asymptomatic group showed a linear decline in over the same period  (Fig 2B) (extra 
sum of squares F-test, p=0.8, do not reject null hypothesis). At the end of the luteal 
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phase,  1-3 days prior to onset of menstruation at day 0, the decline in progesterone 
concentration in women who developed symptoms of PMS followed a steep linear 
trajectory (r2=0.99). The slope of the regression line fitted to the data  during this 
period was significantly steeper than the slope for the participants who remained 
asymptomatic (P<0.05, Extra Sum of Squares F-Test).   
2.3.5. Participants with atypical cycles (n=6) 
Although we initially excluded from the main data set those participants who did not 
menstruate within 20 days of their estimated date of ovulation, it proved instructive to 
examine their salivary progesterone concentration and DRSP scores. In this group 
the basal DRSP scores on the first day of data collection were significantly higher 
than the participants who menstruated (37.7±5.8 v. 24.0±1.6, P=0.02, T-test); 
moreover the scores remained stable at this high level throughout the data analysis 
period (Fig 3).  However, mean salivary progesterone concentration at the start of the 
analysis period was not significantly different from the women who menstruated  
(124.8±37.7 v. 187.8±23.8 pg ml-1 for all symptomatic and asymptomatic participants, 
P=0.1, T-test). Moreover, the participants who failed to menstruate within 20 days of 
their estimated date of ovulation did not show a decline in progesterone during the 
collection period (Fig 3), suggesting that these individuals might have been 
undergoing atypical cycles.  
 
 
DISCUSSION  
 
Within our cohort of young healthy Brazilian women 63% reported experiencing 
premenstrual symptoms, which increased in severity over the 10 day long data 
collection period preceding the onset of menstruation. This incidence of premenstrual 
symptoms is in line with reports on women in other developed countries (Campbell et 
al, 1997; Hylan et al, 1999; Johnson et al, 1988). No woman in our study satisfied the 
criteria for PMDD.  
 
Collection of daily saliva samples offers an attractive non-invasive and stress-free 
means to obtain repeated measurements of progesterone (Lewis, 2006). In the 
present study the mean salivary progesterone concentration of all participants 
(excluding those with atypical cycles) at the beginning of our data analysis period (10 
days prior to onset of menstruation) was similar to that reported during the early 
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luteal phase using ELISA (Gandara et al, 2007). Higher values have been reported 
using radio-immunoassay (Chatterton et al, 2005; Celec et al, 2009), and may reflect 
a differential sensitivity between the two forms of assay. Salivary progesterone 
concentration remained essentially stable during the mid-late luteal phase before 
falling during the last 3 days prior to menstruation. A similar salivary hormonal profile 
in during the mid-late luteal phase was reported by Ishikawa et al (2002) and also by 
Ziomkeiwicz et al (2012) in women who showed high luteal phase 
aggression/irritability. However, as noted previously by others (Gann et al 2001; 
Gandara et al 2007), there was considerable between-subject variability, particularly 
in relation to the time course of changes in progesterone concentration over the 
luteal phase collection period. The factors contributing to the variability in these 
studies were not investigated. 
 
In the present study salivary progesterone in asymptomatic women, who showed no 
significant change in subjective complains of premenstrual symptoms during the 
luteal phase, underwent a steady linear decline over the final 10 days leading up to 
menstruation. It seems unlikely that these women failed to ovulate. If they had not 
ovulated, their level of progesterone secretion would be expected to be very low in 
the absence of a corpus luteum, In fact, their peak progesterone concentration at the 
beginning of the collection period did not different significantly from the women who 
developed symptoms of PMS. Moreover, their early luteal phase progesterone was 
similar to that reported previously using an ELISA assay, in saliva of cycling women 
(Gandara et al 2007).  In the women in the present study who developed symptoms 
of PMS, progesterone concentration at the beginning of the data collection period 
was similar to the asymptomatic participants, but remained stable at this level until 3 
days prior to menstruation, when it declined rapidly. This profile is very similar to that 
reported for plasma luteal phase progesterone concentration in women with PMDD 
(Andréen et al, 2006).  
 
At first sight the data from the participants who developed symptoms of PMS appear 
anomalous since premenstrual symptom scores increased during the period when 
progesterone was stable and then increased even further when progesterone 
secretion declined rapidly at the end of the cycle. In animal models anxiolytic and 
even sedative effects of progesterone and its neuroactive metabolites have been 
widely reported following acute administration (Bitran et al, 1991; 1995; Fernandez-
Guasti and Picazo, 1992). However, it is worth noting that at low concentrations, 
which are more likely to produce plasma concentration within the physiological 
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range, these steroids can be anxiogenic or induce aggressive behaviour (Miczek et 
al, 2003; Gulinello and Smith, 2003).  
 
Adverse effects of progesterone on mood may also be exacerbated on chronic 
exposure. In post menopausal women, who have a low level of endogenous 
progesterone, 14 days of repeated administration of progesterone designed to 
produce a stable physiological concentration of the steroid, was associated with a 
progressive worsening of negative mood (Andréen et al, 2006). This finding is 
analogous to the situation in the present study where in participants who developed 
PMS, the symptom score progressively increased during the mid-luteal phase when 
their progesterone concentration was stable i.e. before the rapid fall in the days prior 
to menstruation. Paradoxically, their symptoms continued to worsen when 
progesterone underwent a sharp decline prior to onset of menstruation. In rats, 
withdrawal from chronic dosing with exogenous progesterone has been reported to 
precipitate raised anxiety and increased responsiveness to acute mild psychological 
stress (Smith et al, 1998; 2006; Devall et al, 2009). This effect was shown to be 
mediated not by the native hormone, but by its neuroactive metabolite 
allopregnanolone (Smith et al, 1998).  The withdrawal of the steroid precipitated 
upregulation of α4, β and δ subunits of the GABAA receptor, which was associated 
with increased excitability in brain areas containing nerve circuits associated with 
mediating responsiveness to acute stress (Devall et al, 2009; 2015; Smith et al, 
1998; 2006). Similar effects were reported in spontaneously cycling rats during the 
late diestrus phase of the estrous cycle (Devall et al, 2009; 2015), when 
progesterone declines rapidly but estrogen secretion remains relatively stable 
(Butcher et al, 1974).  Interestingly, a more recent study on women has proposed 
that GABAA receptor dysfunction may be linked to susceptibility to developing PMS, 
based on differences in sensitivity to allopregnanolone during the luteal phase in 
women with premenstrual dysphoric disorder (PMDD) compared to asymptomatic 
individuals (Timby et al, 2016). A similar dysfunction may be present in women who 
develop PMS. 
 
The above findings suggest that two mechanisms could come into play sequentially 
during the luteal phase in women who developed symptoms of PMS. The initial 
increase in symptom score during the early/mid luteal phase may result from 
continued exposure to relatively stable progesterone concentration, followed by 
further exacerbation of symptoms triggered by a withdrawal effect as progesterone 
secretion declines in the late luteal phase. Interestingly, the rate at which 
 14 
progesterone declines appears to be an important determinant of the drug withdrawal 
effect. In a rat model, adverse behavioral changes were precipitated only following a 
rapid withdrawal from long term dosing with progesterone, but did not occur if 
progesterone declined slowly (Doornbos et al, 2009). The latter scenario is 
analogous to the asymptomatic participants in the present study who experienced a 
gradual decline in progesterone during the mid and late luteal phase and who did not 
develop premenstrual symptoms. 
 
A limitation to our study is the absence of follicular phase concentration of 
progesterone for each participant. This would have provided unequivocal evidence of 
ovulation. However, in the participants who menstruated before the end of the 20 day 
collection period (mean onset of menstruation 14.6 days after ovulation), peak 
progesterone concentration was commensurate with the expected values for the 
luteal phase using our assay system (see below). These two factors (menstruation 
and normal luteal phase progesterone) give us confidence that they were cycling 
normally.  In a similar vein, the absence of DSRP scores for the follicular phase did 
not allow us to determine whether, in our presumed asymptomatic group in whom 
DSRP scores remained stable during the collection period, PMS symptoms had 
developed very early post ovulation and remained constant throughout the luteal 
phase. This seems an unlikely scenario however. Our participants scored from 1 (no 
symptoms) up to 6 (severe) on the 14 point DSRP questionnaire. A score of 14 
indicates no symptoms at all, whereas a score of 28, which is the mean early luteal 
phase score for our asymptomatic group, would indicate on average only mild 
symptoms. On the other hand our symptomatic subjects’ mean scores rose steadily 
by 75% to peak in the late luteal phase, consistent with development of PMS.  
 
In the present study 18% of our participants had not menstruated by 20 days after 
their estimated date of ovulation, and were instructed to cease data collection. There 
was no evidence of cyclicity in salivary progesterone concentration in this group and 
the participants also failed to report any significant change in premenstrual 
symptoms during the data collection period. A similar incidence of abnormal 
progesterone profiles has been reported previously and was presumed to reflect 
anovulatory cycles, (Gandara et al 2007) and is in line with the earlier finding in 
women with PMDD that symptoms do not appear during anovulatory cycles 
(Hammarbäck et al 1991). However in our participants who did not menstruate, the 
progesterone concentration was in the range expected during the luteal phase, 
according to the manufacturer’s guidelines for the assay kits we used 
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(www.salimetrics.com/assets/documents/1-1502.pdf). It is possible that the failure to 
menstruate reflected an exceptionally long luteal phase in these women. However, 
even after 20 days of sample collection, there was no sign that progesterone 
concentration was starting to decline (Fig 3), which would be expected as a prelude 
to menstruation.  
 
An interesting feature of this group was that their DRSP scores at the beginning of 
the collection period were very high (higher than the maximum reached by the 
symptomatic group) and remained so throughout the collection period. In rats (males 
and females), we found that exposure to restraint stress evoked a parallel increase in 
secretion of both progesterone and corticosterone from the adrenal cortex (Kalil et al, 
2013). Very recently, a parallel stress-induced increase in secretion of cortisol and 
progesterone has also been reported in humans (men and women) (Juster et al, 
2016). It is possible that the high DRSP scores in our participants who did not 
menstruate were a response to personal stress or other distress at the time of the 
study, which stimulated adrenal secretion of progesterone and interfered with the 
participants’ normal menstrual cycle. Regardless of the underlying source of 
progesterone in these women, the coincident high stable progesterone and high 
stable DSRP scores in this group are interesting because they emphasize that the 
dynamic of the progesterone profile during the luteal phase, rather than the absolute 
level achieved appears to be the key factor that precipitates worsening of 
premenstrual symptoms. A significant increase in severity of premenstrual symptoms 
developed only when progesterone concentration changed abruptly. 
 
The results of the present study suggest that individual differences in secretion or 
metabolism of progesterone during the luteal phase could be determinants of 
susceptibility to developing negative mood symptoms. The critical factor may not be 
the absolute concentration of progesterone reached during the luteal phase but 
rather, the rate at which progesterone declines. The factors that determine individual 
differences in the rate of secretion and/or metabolism progesterone are not clear. 
Progesterone is metabolised to its neuroactive metabolite allopregnanolone via the 
actions of two enzymes:  5α-reductase and 3α-hydroxysteroid reductase. 
Interestingly, the presence of a polymorphism in the cytosine/cytosine (C/C) 
genotype for SRD5A1SNP, rs501999, the gene that encodes for type I 5α-reductase, 
appears to protect women against developing severe premenstrual symptoms 
(Adams and McCrone, 2012). Moreover mice deficient in Type 1 5α-reductase did 
not show the estrous cycle-linked changes in affective behavior displayed by wild 
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type animals (Koonce et al, 2012).  These results suggest that further investigation of 
the activity of Type 1 5α-reductase in relation to metabolism of progesterone and 
susceptibility to PMS is warranted.  
  
Although this study focused on the effect of progesterone and its metabolite 
allopregnanolone, it must be emphasized that these are not the only neuroactive 
steroids to change during the menstrual cycle. Although progesterone is the 
dominant steroid in the luteal phase secretion of estrogen also fluctuates. Estrogen 
can act as a modulator of synaptic plasticity, connectivity, and cognitive behaviors in 
its own right, as well as modulating the effects of progesterone to influence behavior 
during the ovarian cycle (Llaneza and Frye, 2009; Srivastava and Penzes, 2011). It is 
not possible to determine from the present findings, the extent that estrogen may 
have contributed to the development of symptoms of PMS. 
 
 
 
CONCLUSIONS 
 
The present study suggests that the rate of change in progesterone concentration 
during the luteal phase of the cycle could be an important determinant of 
susceptibility to developing the adverse psychological reactions, which characterize 
PMS. However, progesterone should not be considered in isolation. Although beyond 
the scope of the current study, consideration should be given to the influence of 
estrogen as well as progesterone in the development of premenstrual dysphorias. 
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Fig 1. Pooled data from all participants (n=35) to show time course score of mean 
PMS measured by the Daily Record of Severity Problems Scale (DRSP) total score 
and saliva progesterone concentration over the 11 days prior to menstruation. 
**p<0.01; *** P<0.001 compared to Day -10, Friedman test across all days followed 
by Dunn’s multiple comparisons. 
 
Fig 2 A. Time course of mean PMS score and saliva progesterone concentration in 
22 symptomatic women over the 10 days prior to menstruation. ** p<0.01; *** 
compared to Day -10, Friedman test across all days followed by Dunn’s multiple 
comparisons.  
B. Time course of mean PMS score and saliva progesterone concentration in 12 
asymptomatic women over the last 10 days prior to menstruation. Friedman’s test 
across all days followed by Dunn’s test for multiple comparisons revealed no 
significant differences. Lines of best fit were determined by extra sum of squares F-
test (GraphPad PRISM).  
  
 
Fig 3. Time course of mean PMS score and saliva progesterone concentration in 6 
women had not started to menstruate 20 days post their calculated day of ovulation. 
Friedman’s test across all days followed by Dunn’s test for multiple comparisons 
revealed no significant differences. Lines of best fit were determined by extra sum of 
squares F-test (GraphPad PRISM).   
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Table 1: Internal consistency (Cronbach’s Alpha) of the DRSP, according to the total 
score and the subscale of premenstrual symptoms (items 1 to 11 of the DSRP) and 
the subscale of impact of the premenstrual symptoms on the global functioning 
(items 12 to 14). 
 Day 10 Day 9 Day 1 Day 0 
Total score 
 
0.881 0.912 0.926 0.911 
Premenstrual 
Symptoms 
0.865 0.881 0.916 0.899 
Global 
functioning 
0.888 0.854 0.841 0.863 
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Table 2: Intraclass Correlation Coefficient (ICC) of the items of the DRSP applied in 
the early luteal phase and in the late luteal phase. 
 Item of the DRSP Early luteal phase 
(day 10 vs. Day 9) 
Late luteal phase 
(day 1 vs. day 0) 
1 Depressed mood 0.547 0.519 
2 Anxiety 0.687 0.743 
3 Mood fluctuations 0.773 0.771 
4 Irritability 0.839 0.696 
5 Anedhonia 0.532 0.847 
6 Concentration 0.757 0.832 
7 Tiredness 0.596 0.828 
8 Changes in appetite 0.849 0.89 
9 Sleep disturbances 0.627 0.708 
10 Loosing control 0.607 0.677 
11 Physical symptoms 0.858 0.643 
12 Impairment at work/school 0.522 0.78 
13 Impairment of social activities 0.759 0.669 
14 Impairment in relationships 0.705 0.708 
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